[{"address1": "7 Times Square", "address2": "43rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "929 999 4055", "website": "https://dianthustx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.", "fullTimeEmployees": 53, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marino  Garcia M.B.A.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 496022, "exercisedValue": 0, "unexercisedValue": 684805}, {"maxAge": 1, "name": "Mr. Ryan  Savitz", "age": 35, "title": "Chief Financial Officer & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 329651, "exercisedValue": 0, "unexercisedValue": 91701}, {"maxAge": 1, "name": "Mr. Simrat  Randhawa M.B.A., M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 338158, "exercisedValue": 0, "unexercisedValue": 78378}, {"maxAge": 1, "name": "Mr. Edward G. Carr", "age": 55, "title": "Chief Accounting Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Judson  Taylor", "title": "Head of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  Stavenhagen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Davis Ruff", "title": "VP and Head of Investor Relations & Corporate Affairs.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam M. Veness Esq.", "age": 38, "title": "Senior VP, General Counsel & Secretary", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Maximenko", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rashieda  Gluck", "title": "Head of Clinical Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.58, "open": 25.38, "dayLow": 23.19, "dayHigh": 25.38, "regularMarketPreviousClose": 25.58, "regularMarketOpen": 25.38, "regularMarketDayLow": 23.19, "regularMarketDayHigh": 25.38, "trailingPE": 3.3518007, "forwardPE": -7.3556232, "volume": 190269, "regularMarketVolume": 190269, "averageVolume": 246506, "averageVolume10days": 269390, "averageDailyVolume10Day": 269390, "bid": 18.04, "ask": 29.88, "bidSize": 200, "askSize": 200, "marketCap": 716247424, "fiftyTwoWeekLow": 10.65, "fiftyTwoWeekHigh": 33.77, "priceToSalesTrailing12Months": 133.47884, "fiftyDayAverage": 24.8332, "twoHundredDayAverage": 25.92745, "currency": "USD", "enterpriseValue": 435434560, "floatShares": 13636210, "sharesOutstanding": 29597000, "sharesShort": 5661839, "sharesShortPriorMonth": 5442599, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.19129999, "heldPercentInsiders": 0.08758, "heldPercentInstitutions": 1.1172299, "shortRatio": 18.56, "shortPercentOfFloat": 0.2684, "impliedSharesOutstanding": 29597000, "bookValue": 11.506, "priceToBook": 2.1032507, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -67092000, "trailingEps": 7.22, "forwardEps": -3.26, "enterpriseToRevenue": 81.147, "enterpriseToEbitda": -5.258, "52WeekChange": 0.97551024, "SandP52WeekChange": 0.22263205, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "DNTH", "underlyingSymbol": "DNTH", "shortName": "Dianthus Therapeutics, Inc.", "longName": "Dianthus Therapeutics, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1c256785-fa9a-34f5-a846-6abff7f6272e", "messageBoardId": "finmb_631649032", "gmtOffSetMilliseconds": -18000000, "currentPrice": 24.2, "targetHighPrice": 84.0, "targetLowPrice": 36.0, "targetMeanPrice": 51.8, "targetMedianPrice": 51.0, "recommendationKey": "none", "numberOfAnalystOpinions": 10, "totalCash": 281123008, "totalCashPerShare": 9.498, "ebitda": -82814000, "totalDebt": 311000, "quickRatio": 18.065, "currentRatio": 18.3, "totalRevenue": 5366000, "debtToEquity": 0.092, "revenuePerShare": 0.19, "returnOnAssets": -0.18955, "returnOnEquity": -0.25991, "freeCashflow": -43810000, "operatingCashflow": -62590000, "revenueGrowth": 1.351, "grossMargins": 1.0, "operatingMargins": -13.766109, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]